# Empagliflozine vermindert nierletselmarkers bij acuut hartfalen

*geplaatst 2022-08-01 · Hartfalen · ESC heart failure · doi 10.1002/ehf2.13955 · https://hartvaat.nl/2022/08/01/empagliflozine-vermindert-nierletselmarkers-bij-acuut-hartfalen/*

Exploratieve studie toonde dat empagliflozine bij acuut gedecompenseerd hartfalen markers van acute nierschade verminderde, ondanks de verwachte initiële eGFR-daling. Dit ondersteunt de nierbeschermende werking van SGLT2-remmers bij kritisch zieke hartfalenpatiënten.

## English: Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure.

This exploratory study showed that empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure, suggesting renal protective effects of SGLT2 inhibition despite initial eGFR dip.

## Abstract (original, from the publication)

AIMS: In this prospective, placebo-controlled, double-blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patients with acute decompensated heart failure (HF). METHODS AND RESULTS: Patients with acute decompensated HF with or without diabetes were randomized to empagliflozin 10 mg or placebo for 30 days. Haemodynamic, laboratory, and urinary parameters were assessed after 6 h, 1 day, 3 days, 7 days, and 30 days of treatment. Median time between hospital admission and randomization was 72 h. Baseline characteristics were not different in the empagliflozin (n = 10) and placebo (n = 9) groups. Empagliflozin led to a significant increase in urinary glucose excretion throughout the study (baseline: 37 ± 15 mg/24 h; Day 1: 14 565 ± 8663 mg/24 h; P = 0.001). Empagliflozin did not affect the primary endpoint of cardiac index or on systemic vascular resistance index at any time point. However, empagliflozin significantly reduced parameters of AKI (urinary TIMP-2 and IGFBP7 by NephroCheck® as indicators of tubular kidney damage), which became significant after 3 days of treatment [placebo: 1.1 ± 1.1 (ng/mL)2 /1000; empagliflozin: 0.3 ± 0.2 (ng/mL)2 /1000; P = 0.02] and remained significant at the 7 day time point [placebo: 2.5 ± 3.8 (ng/mL)2 /1000; empagliflozin: 0.3 ± 0.2 (ng/mL)2 /1000; P = 0.003]. CONCLUSIONS: In this study, empagliflozin treatment did not affect haemodynamic parameters but significantly reduced markers of tubular injury in patients with acute decompensated HF.

Auteurs: Kirsten Thiele, Matthias Rau, Niels-Ulrik Korbinian Hartmann, Marcus Möller, Julia Möllmann, Joachim Jankowski, András P Keszei, Michael Böhm, Jürgen Floege, Nikolaus Marx, Michael Lehrke

---
Bron: ESC heart failure, https://doi.org/10.1002/ehf2.13955. Bijgewerkt 2026-07-03T18:38:54Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.